KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得

Treatment-aware deep learning enables counterfactual prediction of individual benefit from PARP inhibitors in ovarian cancer.

Jean-Sébastien Frenel, Pierre-Etienne Heudel, Emmanuelle Guinaudeau, Céline Bossard, Carmela Pisano, Giuseppe Caruso, Joseph Rynkiewicz, Sanae Salhi, Yahia Salhi, Jérôme Chetritt, Eric Pujade-Lauraine, Isabelle Ray-Coquard

NPJ Digit Med 10.1038/s41746-026-02822-z

PMID42323410
PMCID-
DOI10.1038/s41746-026-02822-z
发表日期2026-06-20
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

Homologous recombination deficiency (HRD) assays are used to select patients with ovarian cancer for PARP inhibitors, but they do not fully capture the heterogeneity of treatment benefit. Using data from the phase III PAOLA-1 randomized trial, we developed a deep learning model based on diagnostic hematoxylin and eosin whole-slide images from treatment-naive primary tumors to estimate individual benefit from maintenance olaparib plus bevacizumab versus bevacizumab alone. The model combined image-derived features with randomized treatment assignment and progression-free survival data to estimate, for each patient, the risk of progression under both treatments. The difference between these risks defined a continuous Estimated Treatment Improvement (ETI) score, which quantifies patient-level treatment effect. In 421 patients with available pre-treatment slides, ETI showed a strong treatment-biomarker interaction for first progression-free survival (interaction HR 0.36, 95% CI 0.22-0.59; p < 0.005), while HRD status showed a similar interaction magnitude (HR 0.41, 95% CI 0.25-0.64; p < 0.005). ETI remained independently associated with outcome after adjustment for clinical covariates and HRD status. Subgroup and STEPP analyses indicated that ETI further stratified benefit within both HRD-positive and HRD-negative tumors. Attention maps suggested an association between multifocal tumor-infiltrating lymphocytes and predicted benefit from olaparib. These findings suggest that histology-based modeling of heterogeneity of treatment effects may complement HRD testing for treatment decision-making, although external validation remains necessary.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。